Níveis plasmáticos de BDNF em idosas com e sem dor lombar aguda e sua relação com intensidade da dor, sintomas depressivos e uso de medicamentos analgésicos e antidepressivos

Detalhes bibliográficos
Ano de defesa: 2016
Autor(a) principal: Juliano Bergamaschine Mata Diz
Orientador(a): Não Informado pela instituição
Banca de defesa: Não Informado pela instituição
Tipo de documento: Dissertação
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Universidade Federal de Minas Gerais
Programa de Pós-Graduação: Não Informado pela instituição
Departamento: Não Informado pela instituição
País: Não Informado pela instituição
Palavras-chave em Português:
Link de acesso: https://hdl.handle.net/1843/BUBD-ADJRL3
Resumo: Low back pain (LBP) is a multifactorial symptom that has emerged as a major public health problem in the older population worldwide. It affects between 3050% of the older adults aged 60 years and is strongly associated with the presence of disabling pain and depressive disorders. Contemporary research has sought to identify the multiple biological mechanisms involved in LBP complaints. This study compared brain-derived neurotrophic factor (BDNF) plasma levels, a key neurotrophin in pain modulation, between older women after an acute episode of LBP and controls without pain, and investigated potential differences in BDNF levels between controls and LBP subgroups divided according to pain severity, presence of depressive symptoms and current use of analgesic and antidepressant drugs. This is a cross-sectional observational study including 221 community-dwelling older women aged 60 years and older (i.e. 154 with an acute episode of LBP and 67 controls without pain). Sociodemographic and clinical variables were obtained by using a multidimensional questionnaire that included age, schooling, marital status, BMI, physical activity and numbers of comorbidities and medications in use. Pain severity "at the present time" of data collection and "over the past week" before data collection was assessed by using an 11-point Numeric Rating Scale (NRS 010). The scores of NRS 010 were re-coded in three levels of pain severity: mild pain (03); moderate pain (47); and severe pain (810). The presence of depressive symptoms was assessed by using the 15-item Geriatric Depression Scale (GDS-15). BDNF plasma levels were measured with an ELISA kit. The age of participants ranged from 62 to 88 years (mean ± SD of 70.8 ± 5.3). There was no significant difference between controls and LBP group with regarding to age, schooling and marital status. BDNF levels in LBP group were significantly higher as compared to controls (7515.9 ± 3021.2 vs 6331.8 ± 3364.0 pg/mL, p=0.005). The estimated mean difference between the two groups was 1184.1 (95% CI 281.7 to 2086.5) pg/mL. BDNF levels were significantly higher in LBP subgroups as compared to controls, regardless of whether pain severity was mild, moderate or severe "at the present time" (p=0.005, p=0.044 and p=0.030, respectively) and "over the past week" (p=0.024, p=0.022 and p=0.029, respectively); if there was presence (p=0.029) or absence (p=0.003) of depressive symptoms; and if participants made current use (p=0.019) or not (p=0.008) of analgesic drugs. However, there were no significant differences in BDNF levels among LBP subgroups with mild, moderate and severe pain at both pain assessment periods (p>0.05); presence or absence of depressive symptoms (p=0.758); and with or without the current use of analgesic drugs (p=0.589). On the other hand, BDNF levels were significantly higher in LBP subgroup without the current use of antidepressant drugs as compared to LBP subgroup with the current use of antidepressant drugs (p=0.046) and controls (p=0.008). However, there was no significant difference in BDNF levels between LBP subgroup with the current use of antidepressant drugs and controls (p=0.442). The results support the increased BDNF plasma levels in older women after an acute episode of LBP. BDNF levels were not associated with pain severity, presence of depressive symptoms and with the current use of analgesic drugs. Future studies should investigate the mechanisms that lead to increased BDNF plasma levels in older women with acute LBP. Additionally, for clinical settings, the aware that the occurrence of LBP in older adults is an intricate and multifactorial symptom, with associated factors that go beyond the musculoskeletal and biomechanical aspects should be considered by physiotherapists and health professionals both in assessment issues as in therapeutic approaches focused to this population.
id UFMG_714da3babe5e08bb8a0a15199f1daa9d
oai_identifier_str oai:repositorio.ufmg.br:1843/BUBD-ADJRL3
network_acronym_str UFMG
network_name_str Repositório Institucional da UFMG
repository_id_str
spelling 2019-08-09T12:48:43Z2025-09-08T23:17:15Z2019-08-09T12:48:43Z2016-06-21https://hdl.handle.net/1843/BUBD-ADJRL3Low back pain (LBP) is a multifactorial symptom that has emerged as a major public health problem in the older population worldwide. It affects between 3050% of the older adults aged 60 years and is strongly associated with the presence of disabling pain and depressive disorders. Contemporary research has sought to identify the multiple biological mechanisms involved in LBP complaints. This study compared brain-derived neurotrophic factor (BDNF) plasma levels, a key neurotrophin in pain modulation, between older women after an acute episode of LBP and controls without pain, and investigated potential differences in BDNF levels between controls and LBP subgroups divided according to pain severity, presence of depressive symptoms and current use of analgesic and antidepressant drugs. This is a cross-sectional observational study including 221 community-dwelling older women aged 60 years and older (i.e. 154 with an acute episode of LBP and 67 controls without pain). Sociodemographic and clinical variables were obtained by using a multidimensional questionnaire that included age, schooling, marital status, BMI, physical activity and numbers of comorbidities and medications in use. Pain severity "at the present time" of data collection and "over the past week" before data collection was assessed by using an 11-point Numeric Rating Scale (NRS 010). The scores of NRS 010 were re-coded in three levels of pain severity: mild pain (03); moderate pain (47); and severe pain (810). The presence of depressive symptoms was assessed by using the 15-item Geriatric Depression Scale (GDS-15). BDNF plasma levels were measured with an ELISA kit. The age of participants ranged from 62 to 88 years (mean ± SD of 70.8 ± 5.3). There was no significant difference between controls and LBP group with regarding to age, schooling and marital status. BDNF levels in LBP group were significantly higher as compared to controls (7515.9 ± 3021.2 vs 6331.8 ± 3364.0 pg/mL, p=0.005). The estimated mean difference between the two groups was 1184.1 (95% CI 281.7 to 2086.5) pg/mL. BDNF levels were significantly higher in LBP subgroups as compared to controls, regardless of whether pain severity was mild, moderate or severe "at the present time" (p=0.005, p=0.044 and p=0.030, respectively) and "over the past week" (p=0.024, p=0.022 and p=0.029, respectively); if there was presence (p=0.029) or absence (p=0.003) of depressive symptoms; and if participants made current use (p=0.019) or not (p=0.008) of analgesic drugs. However, there were no significant differences in BDNF levels among LBP subgroups with mild, moderate and severe pain at both pain assessment periods (p>0.05); presence or absence of depressive symptoms (p=0.758); and with or without the current use of analgesic drugs (p=0.589). On the other hand, BDNF levels were significantly higher in LBP subgroup without the current use of antidepressant drugs as compared to LBP subgroup with the current use of antidepressant drugs (p=0.046) and controls (p=0.008). However, there was no significant difference in BDNF levels between LBP subgroup with the current use of antidepressant drugs and controls (p=0.442). The results support the increased BDNF plasma levels in older women after an acute episode of LBP. BDNF levels were not associated with pain severity, presence of depressive symptoms and with the current use of analgesic drugs. Future studies should investigate the mechanisms that lead to increased BDNF plasma levels in older women with acute LBP. Additionally, for clinical settings, the aware that the occurrence of LBP in older adults is an intricate and multifactorial symptom, with associated factors that go beyond the musculoskeletal and biomechanical aspects should be considered by physiotherapists and health professionals both in assessment issues as in therapeutic approaches focused to this population.Universidade Federal de Minas GeraisIdosoDor lombarDepressãoFator neurotrófico derivado do cérebroEnvelhecimentoIdososDor lombarDepressao em idososEnvelhecimentoNíveis plasmáticos de BDNF em idosas com e sem dor lombar aguda e sua relação com intensidade da dor, sintomas depressivos e uso de medicamentos analgésicos e antidepressivosinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisJuliano Bergamaschine Mata Dizinfo:eu-repo/semantics/openAccessporreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGLeani Souza Maximo PereiraDaniele Sirineu PereiraDiogo Carvalho FelícioA dor lombar (DL) é um sintoma de etiologia multifatorial que tem emergido como um importante problema de saúde pública na população idosa em todo o mundo. Afeta entre 30 e 50% dos idosos com idade de 60 anos ou mais e está fortemente associada com a presença de incapacidade e sintomas depressivos. Nos últimos anos, uma nova vertente de pesquisas no campo da biologia da dor tem buscado identificar os múltiplos mecanismos envolvidos na DL. Esta dissertação teve como objetivo principal comparar os níveis plasmáticos do fator neurotrófico derivado do cérebro (brain-derived neurotrophic factor - BDNF), uma neurotrofina chave na modulação da dor, entre idosas com DL aguda e idosas controles livres de qualquer dor, e como objetivo secundários investigar possíveis diferenças nos níveis de BDNF entre as idosas sem dor e subgrupos de idosas com DL aguda agrupadas conforme a intensidade da dor, presença de sintomas depressivos e uso atual de analgésicos e antidepressivos. Foi realizado um estudo observacional do tipo transversal com uma amostra de 221 mulheres idosas comunitárias com idade de 60 anos ou mais. Foram incluídas idosas que apresentaram um novo episódio agudo de DL (n=154) e idosas livres que qualquer dor (n=67). Para a caracterização da amostra foi aplicado um questionário multidimensional que incluiu variáveis sociodemográficas e clínicas tais como idade, escolaridade, estado civil, índice de massa corporal, atividade física, presença de comorbidades e uso de medicamentos. A intensidade da dor no momento da avaliação e na semana anterior à avaliação foi mensurada pela Escala Numérica de Dor (END 010), a qual teve seus escores categorizados em dor leve (03), moderada (47) e intensa (810). Os sintomas depressivos foram avaliados por meio da Escala de Depressão Geriátrica de 15 itens (EDG-15). Os níveis plasmáticos de BDNF foram mensurados por meio de um kit de ELISA para BDNF humano. A média de idade da amostra foi de 70,8 ± 5,3 (amplitude de 62 a 88) anos. Não houve diferença significativa entre os grupos de idosas com DL e sem dor com relação à idade, escolaridade e estado civil. Os níveis de BDNF foram significativamente maiores no grupo de idosas com DL em comparação com grupo de idosas sem dor (7515,9 ± 3021,2; Md=7116,0 pg/mL vs 6331,8 ± 3364,0; Md=5897,5 pg/mL, p=0,005). A diferença média estimada entre os níveis de BDNF dos dois grupos foi de 1184,1 (IC 95% 281,7 a 2086,5) pg/mL. Os níveis de BDNF foram significativamente maiores nos subgrupos de idosas com DL em comparação com o grupo de idosas sem dor, independente se a intensidade da dor foi leve, moderada ou intensa no momento da avaliação (p=0,005, p=0,044 e p=0,030, respectivamente) e na semana anterior à avaliação (p=0,024, p=0,022 e p=0,029, respectivamente); se havia presença (p=0,029) ou ausência (p=0,003) de sintomas depressivos; e se as participantes fizeram uso atual (p=0,019) ou não (p=0,008) de analgésicos. Entretanto, não houve diferenças significativas nos níveis de BDNF entre os subgrupos de idosas com DL com: dor leve, moderada e intensa em ambos os períodos de avaliação (p>0,05); presença ou ausência de sintomas depressivos (p=0,758); e com uso atual ou não de analgésicos (p=0,589). Por outro lado, os níveis de BDNF foram significativamente maiores no subgrupo de idosas com DL sem uso atual de antidepressivos em comparação com o subgrupo de idosas com DL com uso atual de antidepressivos (p=0,046) e com o grupo de idosas sem dor (p=0,008). Entretanto, não houve diferença significativa nos níveis de BDNF entre o subgrupo de idosas com DL com uso atual de antidepressivos e o grupo de idosas sem dor (p=0,442). Os resultados encontrados suportam o aumento dos níveis plasmáticos de BDNF em idosas após um episódio agudo de DL. Os níveis de BDNF não foram associados com intensidade da dor, presença de sintomas depressivos e uso atual de analgésicos. Futuros estudos devem investigar os mecanismos que levam ao aumento dos níveis plasmáticos de BDNF em idosas com DL aguda. Ademais, no âmbito clínico, o entendimento de que a DL na população idosa é um sintoma complexo e multifatorial, com fatores associados que vão além dos componentes osteomioarticulares e da biomecânica corporal, deve ser considerado pelos fisioterapeutas e profissionais de saúde tanto nos procedimentos de avaliação quanto nas abordagens terapêuticas para essa população.UFMGORIGINALdissertacao_mestrado_final_juliano_bergamaschine_mata_diz.pdfapplication/pdf3022219https://repositorio.ufmg.br//bitstreams/6de9e3bc-4ddd-49b2-b4af-460f3a571cc5/download50092f85a8d028b09b35920a22bf57aaMD51trueAnonymousREADTEXTdissertacao_mestrado_final_juliano_bergamaschine_mata_diz.pdf.txttext/plain215068https://repositorio.ufmg.br//bitstreams/c3dbb8bb-e99c-4b0c-a316-2486eb38aac8/download285fd3c02968da052730717845c71fe1MD52falseAnonymousREAD1843/BUBD-ADJRL32025-09-08 20:17:15.609open.accessoai:repositorio.ufmg.br:1843/BUBD-ADJRL3https://repositorio.ufmg.br/Repositório InstitucionalPUBhttps://repositorio.ufmg.br/oairepositorio@ufmg.bropendoar:2025-09-08T23:17:15Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false
dc.title.none.fl_str_mv Níveis plasmáticos de BDNF em idosas com e sem dor lombar aguda e sua relação com intensidade da dor, sintomas depressivos e uso de medicamentos analgésicos e antidepressivos
title Níveis plasmáticos de BDNF em idosas com e sem dor lombar aguda e sua relação com intensidade da dor, sintomas depressivos e uso de medicamentos analgésicos e antidepressivos
spellingShingle Níveis plasmáticos de BDNF em idosas com e sem dor lombar aguda e sua relação com intensidade da dor, sintomas depressivos e uso de medicamentos analgésicos e antidepressivos
Juliano Bergamaschine Mata Diz
Idosos
Dor lombar
Depressao em idosos
Envelhecimento
Idoso
Dor lombar
Depressão
Fator neurotrófico derivado do cérebro
Envelhecimento
title_short Níveis plasmáticos de BDNF em idosas com e sem dor lombar aguda e sua relação com intensidade da dor, sintomas depressivos e uso de medicamentos analgésicos e antidepressivos
title_full Níveis plasmáticos de BDNF em idosas com e sem dor lombar aguda e sua relação com intensidade da dor, sintomas depressivos e uso de medicamentos analgésicos e antidepressivos
title_fullStr Níveis plasmáticos de BDNF em idosas com e sem dor lombar aguda e sua relação com intensidade da dor, sintomas depressivos e uso de medicamentos analgésicos e antidepressivos
title_full_unstemmed Níveis plasmáticos de BDNF em idosas com e sem dor lombar aguda e sua relação com intensidade da dor, sintomas depressivos e uso de medicamentos analgésicos e antidepressivos
title_sort Níveis plasmáticos de BDNF em idosas com e sem dor lombar aguda e sua relação com intensidade da dor, sintomas depressivos e uso de medicamentos analgésicos e antidepressivos
author Juliano Bergamaschine Mata Diz
author_facet Juliano Bergamaschine Mata Diz
author_role author
dc.contributor.author.fl_str_mv Juliano Bergamaschine Mata Diz
dc.subject.por.fl_str_mv Idosos
Dor lombar
Depressao em idosos
Envelhecimento
topic Idosos
Dor lombar
Depressao em idosos
Envelhecimento
Idoso
Dor lombar
Depressão
Fator neurotrófico derivado do cérebro
Envelhecimento
dc.subject.other.none.fl_str_mv Idoso
Dor lombar
Depressão
Fator neurotrófico derivado do cérebro
Envelhecimento
description Low back pain (LBP) is a multifactorial symptom that has emerged as a major public health problem in the older population worldwide. It affects between 3050% of the older adults aged 60 years and is strongly associated with the presence of disabling pain and depressive disorders. Contemporary research has sought to identify the multiple biological mechanisms involved in LBP complaints. This study compared brain-derived neurotrophic factor (BDNF) plasma levels, a key neurotrophin in pain modulation, between older women after an acute episode of LBP and controls without pain, and investigated potential differences in BDNF levels between controls and LBP subgroups divided according to pain severity, presence of depressive symptoms and current use of analgesic and antidepressant drugs. This is a cross-sectional observational study including 221 community-dwelling older women aged 60 years and older (i.e. 154 with an acute episode of LBP and 67 controls without pain). Sociodemographic and clinical variables were obtained by using a multidimensional questionnaire that included age, schooling, marital status, BMI, physical activity and numbers of comorbidities and medications in use. Pain severity "at the present time" of data collection and "over the past week" before data collection was assessed by using an 11-point Numeric Rating Scale (NRS 010). The scores of NRS 010 were re-coded in three levels of pain severity: mild pain (03); moderate pain (47); and severe pain (810). The presence of depressive symptoms was assessed by using the 15-item Geriatric Depression Scale (GDS-15). BDNF plasma levels were measured with an ELISA kit. The age of participants ranged from 62 to 88 years (mean ± SD of 70.8 ± 5.3). There was no significant difference between controls and LBP group with regarding to age, schooling and marital status. BDNF levels in LBP group were significantly higher as compared to controls (7515.9 ± 3021.2 vs 6331.8 ± 3364.0 pg/mL, p=0.005). The estimated mean difference between the two groups was 1184.1 (95% CI 281.7 to 2086.5) pg/mL. BDNF levels were significantly higher in LBP subgroups as compared to controls, regardless of whether pain severity was mild, moderate or severe "at the present time" (p=0.005, p=0.044 and p=0.030, respectively) and "over the past week" (p=0.024, p=0.022 and p=0.029, respectively); if there was presence (p=0.029) or absence (p=0.003) of depressive symptoms; and if participants made current use (p=0.019) or not (p=0.008) of analgesic drugs. However, there were no significant differences in BDNF levels among LBP subgroups with mild, moderate and severe pain at both pain assessment periods (p>0.05); presence or absence of depressive symptoms (p=0.758); and with or without the current use of analgesic drugs (p=0.589). On the other hand, BDNF levels were significantly higher in LBP subgroup without the current use of antidepressant drugs as compared to LBP subgroup with the current use of antidepressant drugs (p=0.046) and controls (p=0.008). However, there was no significant difference in BDNF levels between LBP subgroup with the current use of antidepressant drugs and controls (p=0.442). The results support the increased BDNF plasma levels in older women after an acute episode of LBP. BDNF levels were not associated with pain severity, presence of depressive symptoms and with the current use of analgesic drugs. Future studies should investigate the mechanisms that lead to increased BDNF plasma levels in older women with acute LBP. Additionally, for clinical settings, the aware that the occurrence of LBP in older adults is an intricate and multifactorial symptom, with associated factors that go beyond the musculoskeletal and biomechanical aspects should be considered by physiotherapists and health professionals both in assessment issues as in therapeutic approaches focused to this population.
publishDate 2016
dc.date.issued.fl_str_mv 2016-06-21
dc.date.accessioned.fl_str_mv 2019-08-09T12:48:43Z
2025-09-08T23:17:15Z
dc.date.available.fl_str_mv 2019-08-09T12:48:43Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/1843/BUBD-ADJRL3
url https://hdl.handle.net/1843/BUBD-ADJRL3
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Universidade Federal de Minas Gerais
publisher.none.fl_str_mv Universidade Federal de Minas Gerais
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFMG
instname:Universidade Federal de Minas Gerais (UFMG)
instacron:UFMG
instname_str Universidade Federal de Minas Gerais (UFMG)
instacron_str UFMG
institution UFMG
reponame_str Repositório Institucional da UFMG
collection Repositório Institucional da UFMG
bitstream.url.fl_str_mv https://repositorio.ufmg.br//bitstreams/6de9e3bc-4ddd-49b2-b4af-460f3a571cc5/download
https://repositorio.ufmg.br//bitstreams/c3dbb8bb-e99c-4b0c-a316-2486eb38aac8/download
bitstream.checksum.fl_str_mv 50092f85a8d028b09b35920a22bf57aa
285fd3c02968da052730717845c71fe1
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)
repository.mail.fl_str_mv repositorio@ufmg.br
_version_ 1862105688235311104